FY17 DOD Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP)

Fiscal Year 2017 (FY17) funding opportunities for the Department of Defense (DOD) Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP) that are being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

Applied Research Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Applied Research Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Applied Research Award (ARA) mechanism, applications MUST specifically address at least one of the FY17 JPC-2/MIDRP ARA Focus Areas related to combat-related or trauma-induced wound infections listed below. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

• Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multipathogen/multi-phenotype characterization of antimicrobial resistance patterns.

• Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical infection management decisions (e.g., optimal wound closure time, optimal duration of antibiotic administration for osteomyelitis).

• Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more MDROs, particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extendedspectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

• Preference will be given to studies leading toward topical treatments for prevention and management of wound infection.

Clinical Study Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Clinical Study Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Clinical Study Award (CSA) mechanism, applications MUST contain only one clinical trial/testing with a distinct study design and address at least one of the Focus Areas listed below. Applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

Therapeutics. Evaluation of optimum preventive or directive therapies for combatrelated or trauma-induced wound infections using Food and Drug Administration (FDA)-approved drugs, biologics, or devices either alone or in combination. Studies focusing on new indications of FDA-approved drugs/biologics/devices or investigational new drugs/biologics/devices will be accepted.

Rapid detection of pathogens and/or anti-microbial drug resistance markers. Evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or anti-microbial drug resistance markers in combat-related or traumainduced wounds. Research outcomes should support the development of an FDA regulated device or assay.

  • Rapid detection of biomarkers. Evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization. Research outcomes should support the development of an FDA-regulated device or assay.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more multidrug-resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

Advertisements

Emerging Infections Sentinel Networks (EISN) Research

infectious disease

RFA-CK-16-001

Emerging Infections Sentinel Networks (EISN) Research
Department of Health and Human Services
Centers for Disease Control and Prevention

1. Background and Purpose
In its 1994 monograph, “Addressing Emerging Infectious Disease Threats — A Prevention Strategy for the United States”, the Centers for Disease Control and Prevention (CDC) called for the establishment of provider-based Emerging Infections Sentinel Networks (EISNs) to study conditions that are not covered by health department surveillance and are more likely to be seen by specific kinds of health providers. Therefore, three provider-based networks have been established through CDC’s EISN cooperative agreement program:

The Infectious Diseases Society of America (IDSA) Emerging Infections Network (EIN); An emergency department-based infectious diseases network (Emergency ID Net) of academically-affiliated emergency departments for research on emerging infectious diseases; and The Global Surveillance Network (GeoSentinel) of the International Society of Travel Medicine (ISTM) and CDC. The Emerging Infections Sentinel Network (EISN) program assists awardees in operating provider-based sentinel networks. These networks will contribute to surveillance for emerging infectious diseases, including those caused by drug-resistant, foodborne or waterborne microorganisms, and vaccine-preventable or potentially vaccine-preventable diseases, and will enhance information exchange.

The purpose of this FOA is to provide a funding mechanism for EISN research activities, specifically within a national network of geographically-distributed emergency departments (EDs) in the United States. Healthy People 2020 and other National Strategic Priorities These networks address Healthy People 2020 focus areas and/or CDC Winnable Battles and strategic priorities including: a) access to health services, b) global health, c) health communication and health information technology, d) healthcare-associated infections, e) immunization and infectious diseases, f) preparedness, and g) surveillance.

Objectives/Outcomes
EISN Research Objectives: Research objectives for the provider-based sentinel networks include investigations of various emerging infections and implementation of studies to examine risk factors, determine practice guidelines, and evaluate
outcomes. This FOA specifically aims to support the collection of infectious disease (ID) data from academically-affiliated emergency departments. Emergency departments are considered an invaluable source of ID data for several reasons. EDs treat large numbers of persons, persons with acute and severe disease, persons with clinical syndromes, persons with community-acquired infections, and at-risk populations. EDs can collect prospective data in real time and usually have hospital laboratories available to them. They can also serve as first-line detection and defense of public health threats and emerging infectious diseases. Specific research objectives for a Network of Emergency Departments: To provide descriptive epidemiology and/or assess risk factors for antibiotic-resistant pathogens among patients presenting to emergency departments (potentially, including specimen collection); To describe the epidemiology of antimicrobial use in ED patients; To provide descriptive epidemiology of infectious disease events occurring in metropolitan and/or rural areas nationwide; To be a sentinel network for detection of and rapid response to naturally-occurring and intentional outbreaks; To study the preparedness of EDs and healthcare facilities to assess, manage, triage, and treat individuals suspected of carrying highly infectious diseases.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-CK-16-001
Funding Opportunity Title: Emerging Infections Sentinel Networks (EISN) Research
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 1
CFDA Number(s): 93.860 — Emerging Infections Sentinel Networks
Cost Sharing or Matching Requirement: No
Posted Date: Oct 23, 2015
Creation Date: Oct 23, 2015
Original Closing Date for Applications: Jan 8, 2016  Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date.
Current Closing Date for Applications: Jan 8, 2016   Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date.
Archive Date: Feb 7, 2016
Estimated Total Program Funding: $2,000,000
Award Ceiling: $0
Award Floor: $0

Eligibility

Eligible Applicants:
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Additional Information on Eligibility: Single Source: Olive View-UCLA Education and Research Institute

Additional Information

Agency Name: Centers for Disease Control and Prevention
Description: The Emerging Infections Sentinel Network (EISN) program assists awardees in operating provider-based sentinel networks. These networks will contribute to surveillance for emerging infectious diseases, including drug-resistant, foodborne and waterborne, and vaccine-preventable or potentially vaccine-preventable diseases, and will enhance information exchange. Research objectives for the provider-based sentinel networks include investigations of various emerging infections and implementation of studies to examine risk factors, determine practice guidelines, and evaluate outcomes. This FOA specifically aims to support the collection of infectious disease (ID) data from academically affiliated emergency departments.
Link to Additional Information:  http://www.grants.gov/web/grants/view-opportunity.html?oppId=279769
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Amy Yang vdz9@cdc.gov
Grants Policy